Navigation Links
EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting

isorder (MDD). The trial is designed to evaluate the effect of treatment with up to 120 mg of PRX-00023 twice-daily for eight weeks as determined by change from baseline in MADRS compared with placebo. Data from this trial are expected in the first half of 2008.

About PRX-00023

PRX-00023 is a novel, highly selective, once-daily, 5-HT1A partial agonist discovered using the company's proprietary G-Protein Coupled Receptors (GPCR) modeling, screening and lead optimization technology. PRX-00023 is targeting a significant unmet medical need and commercial opportunity for a selective, once-daily, 5-HT1A agonist used in the treatment of depression that avoids the sexual dysfunction, withdrawal symptoms and sleep disturbances typically associated with selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs), lacks the addictive and sedative effects of the benzodiazepines, and does not have the slow onset, short half-life, and side effects of a chemical class of 5-HT1A agonists called azapirones. PRX-00023 is the subject of a composition of matter patent held by EPIX which extends through 2024.

About EPIX

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, PRX-03140 which is in a Phase 2a clinical trial in Alzheimer's disease, PRX-00023 which is in Phase 2b clinical development to treat major depression, and PRX-07034, which recently completed a Phase 1b trial and is in cli
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/23/2015)... CHAPEL HILL, N.C. , Jan. 23, 2015 For ... organizations are in dealing with payers. Likewise, the importance of ... payers - will only continue to grow as payer formularies ... patients access therapies. At the same time, managed ...
(Date:1/23/2015)... LOS ANGELES , Jan. 23, 2015 A lot ... the best methods for treating  certain illnesses, injuries, or conditions. ... to replace previous treatment methods with ones that they consider ... treating hernias, there is not one textbook method of treatment ...
(Date:1/23/2015)... 23, 2015  A new analysis of Centers for Medicare ... data shows that 81 percent of seniors chose lower-cost ... discounts at certain pharmacies. The findings were released by ... are now the foundation of Medicare Part D," said ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2No One-Size-Fits-All Remedy for Hernia Correction 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... A milestone in lupus research was met this weekend!  On ... held its 8th annual New York City Walk with Us ... matched by the enthusiasm of the nearly 3000 walkers in attendance ... master of ceremonies, My9 news anchor Brenda Blackmon, ALR Chairman Robert ...
... LOUIS, Oct. 27, 2011 Express Scripts, Inc. (Nasdaq: ... following investor conferences in November: Credit Suisse 2011 ... mountain (9:30 a.m. eastern). Lazard Capital Markets, 8th ... a.m. eastern. These presentations will also be ...
Cached Medicine Technology:Alliance for Lupus NYC Walk With Us to Cure Lupus First Lupus Walk In History To Raise $1-Million 2
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... country in the world to legislate healthcare for transsexualism ... this was considered to be radical. It was expected ... group would improve, now that state-financed healthcare was available ... of Gothenburg, Sweden, however, describes this care as an ...
... Reporter , TUESDAY, Nov. 15 (HealthDay News) -- Dieters appear ... intensive weight-loss counseling, two different studies suggest. Even if ... it can translate to more weight loss, the experts found. ... The studies will be presented this week at the American ...
... -- People with heart conditions who take vitamins may be ... according to a new study. Researchers from the Intermountain ... heartbeat -- known as atrial fibrillation -- what they knew ... were also asked how well they followed their prescription for ...
... Sophia Antipolis, 15 November 2011: People taking anti-psychotic drugs and ... an acute coronary event of a fatal arrhythmia than the ... the European Heart Journal .1 The study showed ... was associated with an even greater risk of sudden cardiac ...
... lengthy process. An early sign that it has begun is ... the insulin-producing beta cells are able to compensate for the ... blood sugar levels remain normal. It is not until the ... type 2 diabetes becomes a fact. The latter stage generally ...
... Nov. 15 (HealthDay News) -- Preliminary trials indicate that ... while lowering bad cholesterol shows considerable promise, both on ... The drug evacetrapib is part of a class ... Evacetrapib is the second CETP medication to undergo testing ...
Cached Medicine News:Health News:Health care of transsexual persons causes unnecessary suffering 2Health News:Health care of transsexual persons causes unnecessary suffering 3Health News:Looking to Lose Weight? Get a 'Coach' 2Health News:Looking to Lose Weight? Get a 'Coach' 3Health News:Heart Patients Using Vitamins May Take Meds Improperly 2Health News:Heart Patients Using Vitamins May Take Meds Improperly 3Health News:EHJ paper underlines need for improved links between cardiologists and psychiatrists 2Health News:EHJ paper underlines need for improved links between cardiologists and psychiatrists 3Health News:Molecular link between diabetes and cancer described 2Health News:Cholesterol Drug Shows Promise in Early Research 2Health News:Cholesterol Drug Shows Promise in Early Research 3
RapidStrep A test is a qualitative test that detects group A,streptococcal antigen. The test is a rapid, in vitro assay. It is,intended for professional use to help diagnose Strep A,infection i...
... caused by the intracellular parasite Toxoplasma gondii ... or by contract with cat,feces containing oocytes. ... be passed to the fetus through the ... is a cause of mortality and malformation.,This ...
... an immunochromatographic in vitro assay,for detection ... infection.,Infectious mononucleosis (IM) is caused by ... is based on detection of,serum antibodies ... the,heterophile antibodies present in the sera ...
Inquire...
Medicine Products: